Recently, the SUMMIT trial assessed the dual GIP/GLP‐1 RA tirzepatide (subcutaneous, once‐weekly, up to 15 mg) in 731 patients with obesity‐related HFpEF (LVEF ≥50%; median BMI 38 kg/m2). This evidence concerns the gene GIP and obesity disorder.